Although we have not evaluated cataplexy-like behavior and sleep pattern in our rats as it has been done in mice (Mahoney et al., 2020; Kaushik et al., 2021), it seems that the 30 mg/kg dose of suvorexant in the rat experimental model is able to reproduce a functional situation present in NT1 patients, despite the fact that the cells of the Hcrt/Ox system would be undamaged. This evidence concerns the gene HCRT and Cataplexy.